Results 191 to 200 of about 14,685,767 (350)

Recurrent transfusion‐related acute lung injury after fresh frozen plasma in a patient with hereditary factor V deficiency [PDF]

, 2008
Alvaro C. Laga, Jonathan D. Kurtis, Joseph Sweeney   +2 more
openalex   +1 more source

Hereditary Factors in Gynecologic Cancer.

The Oncologist, 1998
H. Lynch, M. Casey, Trudy G. Shaw, J. Lynch   +3 more
semanticscholar   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Biological Drivers of IMiD-Induced Peripheral Neuropathy in Multiple Myeloma. [PDF]

EJHaem
Beer SA, Houlston R, Kaiser MF.
europepmc   +1 more source

Changes of clotting and fibrinolytic factors levels during Danazol therapy for application of treatment of hereditary hemorrhagic disease.

, 1985
Jun Yoshii, Shoko SAYAMA, K Okudera, S Yaguchi, Toshitaka Ogawa, Hiroyuki Kashiwagi, Yuriko BABA, Hiroaki Soma   +7 more
openalex   +1 more source

Werner syndrome as a hereditary risk factor for exocrine pancreatic cancer [PDF]

, 2010
Stephen G. Chun, Nelson S. Yee
openalex   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

From Mutation to Manifestation: Penetrance in Amyotrophic Lateral Sclerosis. [PDF]

Genes (Basel)
Richard E, Al-Hajj Vourc'h S, Marouillat S, Beltran S, Blasco H, Corcia P, Vourc'h P.   +6 more
europepmc   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Effect of a polygenic risk score in patients with late-onset, early-onset, familial, or hereditary colorectal cancer. [PDF]

JNCI Cancer Spectr
Klinkhammer H, Spier I, Perne C, Hoffmann P, Büttner R, Schröck E, Redler S, Jahn A, Franke M, Möslein G, Kloor M, Schmidt B, Vangala D, Nguyen HP, Forstner AJ, Steinke-Lange V, Holinski-Feder E, Hüneburg R, Maj C, Engel C, Mayr A, Aretz S.   +21 more
europepmc   +1 more source